207_Combined course Presentations

3) Altered fractionation - Intergroup trial 0096: the current standard in LD-SCLC?

Overall Survival



417 Patients

 All patients received 4 x Cis+Etoposide

 Randomly assigned to receive either

10% gain in OS @ 5 year: 26% vs 16%

45 Gy twice daily (1.5 Gy/bid) or once

daily (1.8 Gy/die)

 Higher rates of G3+ esophageal

toxicity in the accelerated arm

p = 0.04

The schedules were not biologically equivalent!

Turrisi AT et al NEJM 1999;340